$0.73
+0.15 (+26.34%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where HUMA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 1 observational · 2 expanded access · 4 with posted results
Held by 10 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, Hudson Bay Capital Management LP, +5 more) · FINRA short interest 6.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)NCT07730528Rate of events (MACE, AE, AESI, etc.) in all participants implanted with CTEVOpen-label · Treatment | Phase 2 | Not yet recruiting | Biological: Humacyte Coronary Tissue Engineered Vessel (CTEV) | Coronary Artery Disease | 10 | Sep 2030 | ≤ 1,502 d | 2026-07-28 |
| Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairNCT07762794Kaplan-Meier estimated Symvess secondary patencyOpen-label · Treatment | Phase 4 | Not yet recruiting | Biological: Acellular Tissue Engineered Vessel | Vascular Injury, Arterial Injury, Trauma Injury | 125 | Sep 2030 | ≤ 1,502 d | 2026-08-13 |
| An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.NCT07762313Number of Participants with Treatment-Related Adverse EventsOpen-label · Treatment | Phase 3 | Not yet recruiting | Biological: Acellular Tissue Engineered Vessel (Symvess) | Vascular Trauma, Arterial Injury, Arterial Bleeding | 10 | Dec 2028 | ≤ 864 d | 2026-08-13 |
| To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084The number of catheter-free days since randomization to Month 12.Randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Biological: Acellular Tissue Engineered Vessel (ATEV) · Other: AVF | End Stage Renal Disease (ESRD) | 121 | Jun 2027 | ≤ 314 d | 2026-06-26 |
| Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisNCT03183245Proportion of subjects with functional patency at 6 months post study access (SA) creationRandomized · Open-label · Treatment | Phase 3 | Completed | Biological: Human Acellular Vessel (HAV) · Procedure: Arteriovenous fistula (AVF) · Other: Hemodialysis | Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access | 242 | 2024-04-22actual | — | 2025-11-20 |
| Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular TraumaNCT03005418results2026-07-29Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV GroupOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Biological: Acellular Tissue Engineered Vessel (ATEV) | Trauma, Vascular System Injury | 72 | 2023-09-19actual | — | 2026-07-29 |
| An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular TraumaNCT05873959observationalSafety and tolerability of the HAV | — | Completed | Biological: HAV implantation | Trauma, Trauma Injury, Trauma, Multiple, Trauma Blunt | 17 | 2023-05-26actual | — | 2024-11-25 |
| Safety and Efficacy Assessment of HAV in Patients Needing Vascular Access for DialysisNCT04135417results2024-02-23Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAVOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: HAV | Renal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis | 30 | 2021-05-15actual | — | 2024-03-19 |
| Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PADNCT02887859results2023-12-19Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV Implantation SiteOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Human Acellular Vessel (HAV) | Peripheral Artery Disease | 15 | Dec 2020actual | — | 2025-04-18 |
| Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for HemodialysisNCT02644941results2025-03-30Number of Participants With Loss of Secondary PatencyRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Human Acellular Vessel (HAV) · Device: ePTFE graft | Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access | 355 | May 2019actual | — | 2026-08-19 |
| Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PADNCT01872208Change in HAV characteristicsOpen-label · Treatment | Not applicable | Completed | Biological: HAV implantation | Peripheral Arterial Disease, Peripheral Vascular Disease | 20 | 2016-05-30actual | — | 2024-11-13 |
| Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal DiseaseNCT01840956HAVG graft assessmentOpen-label · Treatment | Phase 1 | Completed | Biological: HAVG | End-stage Renal Disease, Kidney Failure, Chronic | 20 | 2016-04-28actual | — | 2022-08-19 |
| Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRDNCT01744418HAVG safety & tolerabilityOpen-label · Treatment | Not applicable | Completed | Device: HAVG graft implantation | End-stage Renal Disease, Kidney Failure, Chronic | 40 | Dec 2014actual | — | 2024-11-13 |
| Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System InjuriesNCT03631056expanded access | — | Approved for marketing | Biological: Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV) | Vascular System Injuries | — | — | — | 2025-08-24 |
| Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis AccessNCT07141641expanded access | — | Temporarily not available | Biological: Acellular Tissue Engineered Vessel (ATEV) | Vascular Diseases, End Stage Renal Disease on Dialysis | — | — | — | 2025-09-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19